Physician profile
David A Pazer
NPI 1710022264
$1,303.21
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,142 · 2020: $142 · 2021: $18.58.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $167.13 | 2019-2020 | |
| Glaxosmithkline, LLC. | $151.83 | 2019-2020 | |
| Novo Nordisk INC | $147.48 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $142.00 | 2019 | |
| Abbvie INC. | $109.97 | 2019 | |
| Allergan, INC. | $74.35 | 2019-2020 | |
| Amgen INC. | $71.89 | 2019 | |
| Merck Sharp & Dohme LLC | $69.68 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $57.82 | 2019 | |
| Janssen Pharmaceuticals, INC | $51.56 | 2019-2021 | |
| Esperion Therapeutics, INC. | $47.54 | 2020 | |
| Novartis Pharmaceuticals Corporation | $43.03 | 2019 | |
| Pfizer INC. | $42.74 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.38 | 2019 | |
| Sanofi-Aventis U.S. LLC | $24.49 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $23.95 | 2019 | |
| Amarin Pharma, INC. | $23.37 | 2019 | |
| Astellas Pharma US INC | $20.00 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Pazer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.